Insight

Karl Semaan: First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma

Karl Semaan/X

Aug 16, 2024, 14:16

Karl Semaan: First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma

Karl Semaan, Postdoctoral Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Just in European Urology, our study on first-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma.

Effort co-led with Talal El Zarif with amazing mentorship from Daniel Heng and Toni Choueiri.”

Source: Karl Semaan/X

Authors: Talal El Zarif, Karl Semaan, Wanling Xie, Marc Eid, Martin Zarba, Wadih Issa, Tian Zhang, Charles B. Nguyen, Ajjai Alva, Catherine C. Fahey, Kathryn E. Beckermann, Jose A. Karam, Matthew T. Campbell, Giuseppe Procopio, Marco Stellato, Sebastiano Buti, Anezka Zemankova, Bohuslav Melichar, Francesco Massari, Veronica Mollica, and Toni K. Choueiri.

adjuvant immunotherapy

adjuvant immunotherapy Ajjai Alva Anezka Zemankova Bohuslav Melichar cancer Catherine C. Fahey Charles B. Nguyen Daniel Heng european urology Francesco Massari Giuseppe Procopio Jose A. Karam Karl Semaan Kathryn E. Beckermann Marc Eid Marco Stellato Martin Zarba Matthew T Campbell OncoDaily Oncology renal cell carcinoma Sebastiano Buti Talal El Zarif Tian Zhang Toni Choueiri Toni K. Choueiri Veronica Mollica Wadih Issa Wanling Xie

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage